SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | Aplastic Anemia & MDS International Foundation
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Clinical Trial: NCT03113643

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This research study is studying a drug as a possible treatment for diagnosis of AML and high-risk MDS.

The interventions involved in this study are:

Status: 
Recruiting
Study Date: 
Mon, 06/26/2017 to Wed, 05/31/2023
Bone Marrow Disease(s): 
  • acute myeloid leukemia (AML)
  • myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
This research study is studying a drug as a possible treatment for diagnosis of AML and high-risk MDS. The interventions involved in this study are: SL-401 Azacitidine Venetoclax